Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C.

IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY International Journal of Hepatology Pub Date : 2016-01-01 Epub Date: 2016-06-15 DOI:10.1155/2016/3852126
Allison M Bell, Jamie L Wagner, Katie E Barber, Kayla R Stover
{"title":"Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C.","authors":"Allison M Bell, Jamie L Wagner, Katie E Barber, Kayla R Stover","doi":"10.1155/2016/3852126","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatitis C virus (HCV) is estimated to affect up to 150 million people worldwide. Despite worldwide prevalence, treatment modalities prior to 2011 remained suboptimal, with low virologic response rates and intolerable side effect profiles. Fortunately, the landscape of treatment for chronic hepatitis C has rapidly evolved since the introduction of HCV NS3/4 protease inhibitors in 2011. Elbasvir, a NS5A inhibitor, combined with grazoprevir, a NS3/4A protease inhibitor, is the latest FDA-approved therapy for patients with genotype 1 or 4 chronic hepatitis C, with or without compensated cirrhosis. This review will focus on the current literature and clinical evidence supporting elbasvir/grazoprevir as first-line therapy in patients with genotypes 1 and 4 chronic hepatitis C. </p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2016 ","pages":"3852126"},"PeriodicalIF":1.5000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/3852126","citationCount":"33","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2016/3852126","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/6/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 33

Abstract

Hepatitis C virus (HCV) is estimated to affect up to 150 million people worldwide. Despite worldwide prevalence, treatment modalities prior to 2011 remained suboptimal, with low virologic response rates and intolerable side effect profiles. Fortunately, the landscape of treatment for chronic hepatitis C has rapidly evolved since the introduction of HCV NS3/4 protease inhibitors in 2011. Elbasvir, a NS5A inhibitor, combined with grazoprevir, a NS3/4A protease inhibitor, is the latest FDA-approved therapy for patients with genotype 1 or 4 chronic hepatitis C, with or without compensated cirrhosis. This review will focus on the current literature and clinical evidence supporting elbasvir/grazoprevir as first-line therapy in patients with genotypes 1 and 4 chronic hepatitis C.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Elbasvir/Grazoprevir:抗丙型肝炎最新药物综述
据估计,全世界有1.5亿人感染丙型肝炎病毒(HCV)。尽管在世界范围内流行,但2011年之前的治疗方式仍然不理想,病毒学反应率低,副作用难以忍受。幸运的是,自2011年引入HCV NS3/4蛋白酶抑制剂以来,慢性丙型肝炎的治疗前景迅速发展。Elbasvir(一种NS5A抑制剂)联合grazoprevir(一种NS3/4A蛋白酶抑制剂)是fda批准的最新治疗1型或4型慢性丙型肝炎伴或不伴代偿性肝硬化患者的药物。本综述将重点关注目前支持elbasvir/grazoprevir作为1型和4型慢性丙型肝炎患者一线治疗的文献和临床证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
International Journal of Hepatology
International Journal of Hepatology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
3.80
自引率
0.00%
发文量
11
审稿时长
15 weeks
期刊介绍: International Journal of Hepatology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to the medical, surgical, pathological, biochemical, and physiological aspects of hepatology, as well as the management of disorders affecting the liver, gallbladder, biliary tree, and pancreas.
期刊最新文献
Utilization of Contrast-Enhanced Ultrasound in Diagnosis of Focal Liver Lesions. Anatomical Variations of the Gallbladder and Bile Ducts: An MRI Study. The Role of Gut Microbiota Modification in Nonalcoholic Fatty Liver Disease Treatment Strategies. Evaluation of Noninvasive Tools for Predicting Esophageal Varices in Patients With Cirrhosis at Tygerberg Hospital, Cape Town. Impact of Renal Replacement Therapy on Outcomes of Living Donor Liver Transplantation for Acute Liver Failure: A Cohort Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1